The Columbia Collaborative HIV/AIDS Clinical Trials Unit (Columbia Collaborative CTU) brings together a dedicated and cohesive group of investigators and two institutions situated in New York City (NYC), one of the epicenters of the US epidemic. This collaboration includes highly experienced investigators and two successful clinical research sites (CRSs) with breadth and depth of expertise in clinical, translational and behavioral HIV research to be responsive to the rapidly evolving research needs in HIV prevention (including passive immunization with single, combination of multiple or multi-specific broadly neutralizing monoclonal antibodies, vaccines, novel antiretroviral-based approaches, and integrated biomedical and socio-behavioral strategies) and HIV therapeutics (including antibodies and long-acting antiretroviral formulations, and antiretroviral-free approaches to remission, biobehavioral interventions to improve adherence and reduce the risk of treatment failure, in addition to tuberculosis, complications and comorbidities), as defined by the Division of AIDS (DAIDS) Clinical Trials Networks (CTNs).
Despite great progress in HIV prevention and treatment, many questions remain to be addressed. The Columbia Collaborative HIV/AIDS Clinical Trials Unit is located in a hot spot of HIV activity and is perfectly positioned to conduct cutting edge clinical trials and contribute to scientific agendas of the DAIDS-sponsored Clinical Trials Networks.
|Franks, Julie; Hirsch-Moverman, Yael; Loquere Jr, Avelino S et al. (2018) Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. AIDS Behav 22:1139-1149|
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Grant, Robert M; Mannheimer, Sharon; Hughes, James P et al. (2018) Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis 66:1712-1721|
|Hermanstyne, Keith A; Green Jr, Harold D; Cook, Ryan et al. (2018) Social Network Support and Decreased Risk of Seroconversion in Black MSM: Results of the BROTHERS (HPTN 061) Study. J Acquir Immune Defic Syndr 78:163-168|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Eshleman, Susan H; Piwowar-Manning, Estelle; Sivay, Mariya V et al. (2018) Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol 99-100:67-70|
|Justman, Jessica E; Nair, Gonasagrie Lulu; Hendrix, Craig W et al. (2018) Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. J Acquir Immune Defic Syndr 78:175-182|
|Fong, Youyi; Shen, Xiaoying; Ashley, Vicki C et al. (2018) Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis 217:1280-1288|
|Tieu, Hong-Van; Laeyendecker, Oliver; Nandi, Vijay et al. (2018) Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 13:e0200269|
|Yang, Cui; Latkin, Carl; Tobin, Karin et al. (2018) An Event-Level Analysis of Condomless Anal Intercourse with a HIV-Discordant or HIV Status-Unknown Partner Among Black Men Who Have Sex with Men from a Multi-site Study. AIDS Behav 22:2224-2234|
Showing the most recent 10 out of 122 publications